Velasco-Murillo V

Language: Spanish
References: 28
Page: 237-242
PDF size: 61.60 Kb.

ABSTRACT

It exists controversies about if the effects and benefits of the esterified estrogens could be similar to those informed for equines, because its chemical composition and biodisponibility are different. Esterified estrogens has not delta 8,9 dehydroestrone, and its absorption and level of maximum plasmatic concentrations are reached very fast. In United States of America and another countries, esterified estrogens has been marketed and using for treatment of climacteric syndrome and prevention of postmenopausal osteoporosis, based on the pharmacopoiea of that country, but the Food and Drug administration (FDA) has not yet authorized up today, a generic version of conjugated estrogens. In Instituto Mexicano del Seguro Social (IMSS) and another institutions of health sector in Mexico, starting in year 2000, it has been used esterified estrogens for medical treatment of climateric and menopausal conditions. For this reason, in this paper we revised the most recent information about pharmacology, chemical composition, clinical use and costs of the conjugated estrogens with the purpose to guide the decisions to purchase this kind of drugs in Mexican heath institutions.

REFERENCES

1. Department of Health & Human Services. Public Health Service. Food and Drug Administration. Center for Drug Evaluation and Research. Approvability of a synthetic generic version of Premarin. III. Regulatory history of Conjugated Estrogens. Memorandum, May 5,1997. United States of America.

2. Bhavnani BR. Pharmacokinetics and pharmacodynamics of conjugated equine estrogens: chemistry and metabolism. Proc Soc Exp Biol & Med 1998;217(1):6-16.

3. Department of Health & Human Services. Public Health Service. Food and Drug Administration. Center for Drug Evaluation and Research. Approvability of a synthetic generic version of Premarin. IV. Characterization of Premarin. Memorandum, May 5,1997. United States of America.

4. Klein R. The composition of Premarin. Int J Fert & Woman Med 1998;43(4):223-227.

5. Department of Health & Human Services. Public Health Service. Food and Drug Administration. Center for Drug Evaluation and Research. Approvability of a synthetic generic version of Premarin. V. Conclusions. Memorandum, May 5, 1997. United States of America.

6. Anonymous. A new conjugated estrogen. The Medical Letter on Drugs and Therapeutics 1999; 41(1058):67-68.

7. Velasco-Murillo V, Navarrete-Hernández E, Cardona-Pérez JA, Madrazo-Navarro M. Atención del climaterio y prevención de las complicaciones de la menopausia en medicina familiar. Rev Med IMSS 1998;36(6):473-476.

8. Velasco-Murillo V, Pozos-Cavanzo JL, Cardona-Pérez JA. Terapia hormonal de reemplazo en el climaterio y la postmenopausia. Rev Med IMSS 2000;38(2):131- 138.

9. Wysowski DK, Golden L, Burke L. Use of menopausal estrogens and medroxyprogesterone acetate in the United States, 1982-1992. Obstet Gynecol 1995;85(1):6-10.

10. Lievertz RW. Pharmacology and pharmacokinetics of estrogens. Am J Obstet Gynecol 1987;156(5):1289-1293.

11. Kuhl H. Pharmacokinetics of oestrogens and progestogens. Maturitas 1990;12(3):171-197.

12. Solerte Sb, Firavanti M, Racchi M, Trabucchi M, Zanetti O, Govoni S. Menopause and estrogen deficiency as a risk factor in dementing illness: hypothesis on the biological basis. Maturitas 1999; 31(2): 95-101.

13. Parrilla-Paricio JJ. Terapia hormonal sustitutiva. Aspectos farmacológicos. En: José Navarro, Joaquín Calaf, Rafael Comino, Javier Ferrer, Emilia Magnani, Parrilla JJ, Pérez-Cano R. El climaterio. Barcelona: Masson, S.A., 2000.

14. Carranza-Lira S. Estrógenos. En: Carranza-Lira S. Terapia Hormonal de Reemplazo. México: McGraw-Hill Interamericana, 2000.

15. Bhavnani BR, Cecutti A, Gerulath A. Pharmacokinetics and pharmacodynamics of a novel estrogen delta 8-estrona in postmenopausal women and men. J Ster Bíochem & Molec Biol 1998;67(2):119-131.

16. Baracat E, Haidar M, Peloso U, Negro-Vilar A. Activity and tissue selectivity of delta (8,9) dehidroestrona sulfate in postmenopausal women. Menopause 1996;3(4):250-251.

17. Bhavnani BR, Cecutti A. Estratab, Estratest and Premarin are not bioequivalent (letter, comment). Am J Obstet Gynecol 1992;167(2):459460.

18. Arteaga E, Villaseca P. Pharmacokinetic comparison between Conpremin (Premarin) and a generic preparation of conjugated estrogens. Climateric 1998;1:284-289.

19. Dey M, Lyttle R, Pickar JH. Recent insights into the varying activity of estrogens. Maturitas 2000;34:S25-S33.

20. Baracat E, Haidar M, López FJ, Picar J, Dey M. Estrogen activity and novel tissue selectivity of delta 8,9 dehydroestrone sulfate in postmenopausal women. J Clin End Metab 1999;84(6):2020-2027.

21. Canto de Cetina TE. Terapia de sustitución hormonal en el climaterio. Rev lnvest Clin 1995;47(1):49-61.

22. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 1994;330(15):1062-1071.

23. United States Pharmacopoiea 23. Official monographs: Estrogens. Conjugated estrogens. Esterified Estrogens. Esterified Estrogens Tablets, p. 627-629. United States of America.

24. Instituto Mexicano del Seguro Social. Dirección de Prestaciones Médicas. Comisión Institucional de Cuadros Básicos de Insumos para la Salud: Cuadro Básico Institucional de Medicamentos. México, 1997.

25. Department of Health & Human Services. Public Health Service. Food and Drug Administration. Center for Drug Evaluation and Research. FDA backgrounder on conjugated estrogens. Memorandum, Dec 17,1999. United States of America.

26. Duramed Pharmaceuticals Inc. Transition Report Pursuant to Section 13. item 1 Bussiness: Conjugated estrogens product status. Memorandum, Cincinatti, Ohio, U.S.A., Dec 3l, 1996.

27. Baluch WM, Gardner JS, Krauss RH, Scholes D. Therapeutic interchange of conjugated and esterified estrogens in a managed care organization. Am J Health Syst Pharm 1999;56:537-542.

28. Instituto Mexicano del Seguro Social. Sistema Único de Información, Subsistema 10 Población y Servicios , 2000.